Cholestatic liver disease in children.
Conditions
Interventions
Intervention 1: Intervention group: The treatment group will be received Lactobacilus sporogenesis probiotic is given in drops for 1 month (5 drops per day in two intervals). Intervention 2: Control g
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Years to 12 Years
Inclusion criteria
Inclusion criteria: age1-12 cholestatic liver failure informed consent
Exclusion criteria
Exclusion criteria: Taking antibiotics for four weeks before the study Active microbial infection History of gastrointestinal bleeding over the past two months History of SBP over the past two months Taking immunosuppressive drugs Immunosuppressed patients Renal failure ( creatinine> 1.5 mg) Electronic imbalance (serum sodium 150 meq / dl, serum potassium 5.5 meq / dl) History of Allergies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Pediatric End-Stage Liver Disease (PELD) score. Timepoint: The results of Lab test for calculation of Pediatric End-Stage Liver Disease (PELD) score will be evaluated one month, three months after finishing the intervention. Method of measurement: Pediatric End-Stage Liver Disease (PELD) Score = 0.480 × Loge (bilirubin mg/dL) + 1.857 × Loge (INR) - 0.687 × Loge (albumin g/dL) + 0.436 (if the patient is less than 1 year old) + 0.667 if the patient has growth failure (< -2 Standard deviation). Then multiply the score by 10 and round to the nearest whole number. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in growth and development. Timepoint: Three months after finishing the study. Method of measurement: Measuring weight by scale and height by stadiometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNasrin Motazedian
Shiraz University of Medical Sciences
Outcome results
None listed